BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32212799)

  • 21. [Isocitrate dehydrogenase gene mutations in acute myeloid leukemia].
    Zhou XJ; Zhang SJ; Qiao C; Shen YF; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):902-6. PubMed ID: 21867611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia.
    Ma QL; Wang JH; Wang YG; Hu C; Mu QT; Yu MX; Wang L; Wang DM; Yang M; Yin XF; Chen FF; Lu SS; Chen J; Zhu ZJ; Chen SJ; Jin J
    Int J Cancer; 2015 Sep; 137(5):1058-65. PubMed ID: 25523507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.
    Middeke JM; Metzeler KH; Röllig C; Krämer M; Eckardt JN; Stasik S; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Brümmendorf TH; Naumann R; Steffen B; Einsele H; Schaich M; Burchert A; Neubauer A; Görlich D; Sauerland C; Schäfer-Eckart K; Schliemann C; Krause SW; Hänel M; Frickhofen N; Noppeney R; Kaiser U; Kaufmann M; Kunadt D; Wörmann B; Sockel K; von Bonin M; Herold T; Müller-Tidow C; Platzbecker U; Berdel WE; Serve H; Baldus CD; Ehninger G; Schetelig J; Hiddemann W; Bornhäuser M; Stölzel F; Thiede C
    Blood Adv; 2022 Mar; 6(5):1394-1405. PubMed ID: 34794176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
    Ahmad F; Mohota R; Sanap S; Mandava S; Das BR
    Asian Pac J Cancer Prev; 2014; 15(3):1247-53. PubMed ID: 24606448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.
    Sloan CE; Luskin MR; Boccuti AM; Sehgal AR; Zhao J; Daber RD; Morrissette JJ; Luger SM; Bagg A; Gimotty PA; Carroll M
    PLoS One; 2016; 11(4):e0153016. PubMed ID: 27050425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia.
    Kuzmanovic M; Tosic N; Colovic N; Karan-Djurasevic T; Spasovski V; Radmilovic M; Nikcevic G; Suvajdzic-Vukovic N; Tomin D; Vidovic A; Virijevic M; Pavlovic S; Colovic M
    Acta Haematol; 2012; 128(4):203-12. PubMed ID: 22906848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Detection of isocitrate dehydrogenase 1 gene mutation in 205 AML patients and its clinical significance].
    Shang Z; Wang D; Xiao M; Geng Z; Wang HX; Wang J; Xu YL; Li TJ; Zhou JF; Li CR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1307-11. PubMed ID: 23257422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
    Ibáñez M; Such E; Cervera J; Luna I; Gómez-Seguí I; López-Pavía M; Dolz S; Barragán E; Fuster O; Llop M; Rodríguez-Veiga R; Avaria A; Oltra S; Senent ML; Moscardó F; Montesinos P; Martínez-Cuadrón D; Martín G; Sanz MA
    J Mol Diagn; 2012 Nov; 14(6):594-601. PubMed ID: 22929312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
    Zhou KG; Jiang LJ; Shang Z; Wang J; Huang L; Zhou JF
    Leuk Lymphoma; 2012 Dec; 53(12):2423-9. PubMed ID: 22616558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.
    Ravandi F; Patel K; Luthra R; Faderl S; Konopleva M; Kadia T; Brandt M; Pierce S; Kornblau S; Andreeff M; Wang X; Garcia-Manero G; Cortes J; Kantarjian H
    Cancer; 2012 May; 118(10):2665-73. PubMed ID: 22020636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.
    Boissel N; Nibourel O; Renneville A; Gardin C; Reman O; Contentin N; Bordessoule D; Pautas C; de Revel T; Quesnel B; Huchette P; Philippe N; Geffroy S; Terre C; Thomas X; Castaigne S; Dombret H; Preudhomme C
    J Clin Oncol; 2010 Aug; 28(23):3717-23. PubMed ID: 20625116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
    Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
    Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
    J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Coexisting Mutations in IDH1/2-Mutated Acute Myeloid Leukemia].
    Jia ZX; Chao HY; Liu J; Cai XH; Qin W; Wu P; Lu XZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1440-1448. PubMed ID: 31607296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
    Chou WC; Chou SC; Liu CY; Chen CY; Hou HA; Kuo YY; Lee MC; Ko BS; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo YY; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
    Blood; 2011 Oct; 118(14):3803-10. PubMed ID: 21828143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
    Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical significance of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
    Mi RH; Lu XD; Wei XD; Fan RH; Yin QS; Hu JY; Wang Q; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Sep; 32(9):610-3. PubMed ID: 22338155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
    Xu Q; Li Y; Lv N; Jing Y; Xu Y; Li Y; Li W; Yao Z; Chen X; Huang S; Wang L; Li Y; Yu L
    Clin Cancer Res; 2017 Aug; 23(15):4511-4522. PubMed ID: 28246275
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.